Biogen Idec Partners with University of Edinburg on MS and MND Research

Biogen Idec just announced that they will be collaborating with the University of Edinburgh in Scotland to further understand multiple sclerosis (MS) and motor neuron disease (MND). The three year collaboration will focus on using the strengths of each partner to identify potential therapeutics for MS and MND. Biogen’s VP of neurology research, Ken Rhodes, said the partnership will “provide an in-depth portrait of the pathophysiology of multiple sclerosis and motor neuron disease, while identifying important new targets for potential therapies.” Biogen is committed to continuing to invest in ALS, in fact, they just announced an ALS-focused “Manhattan Project.” Stay tuned to the ALS Forum for additional updates about this new project!

Biogen Idec just announced that they will be collaborating with the University of Edinburgh in Scotland to further understand multiple sclerosis (MS) and motor neuron disease (MND). The three year collaboration will focus on using the strengths of each partner to identify potential therapeutics for MS and MND. Biogen’s VP of neurology research, Ken Rhodes, said the partnership will “provide an in-depth portrait of the pathophysiology of multiple sclerosis and motor neuron disease, while identifying important new targets for potential therapies.” Biogen is committed to continuing to invest in ALS, in fact, they just announced an ALS-focused “Manhattan Project.” Stay tuned to the ALS Forum for additional updates about this new project!

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail